The ZAP-70 tyrosine kinase plays a critical role in T cell activation and the immune response and therefore is a logical target for immunomodulatory therapies. Although the crystal structure of the tandem Src homology-2 domains of human ZAP-70 in complex with a peptide derived from the subunit of the T cell receptor has been reported (Hatada, M. H., Lu, X., Laird, E. R., Green, J., Morgenstern, J. P., Lou, M., Marr, C. S., Phillips, T. B., Ram, M. K., Theriault, K., Zoller, M. J., and Karas, J. L. (1995) Nature 377, 32-38), the structure of the kinase domain has been elusive to date. We crystallized and determined the three-dimensional structure of the catalytic subunit of ZAP-70 as a complex with staurosporine to 2.3 Å resolution, utilizing an active kinase domain containing residues 327-606 identified by systematic N-and C-terminal truncations. The crystal structure shows that this ZAP-70 kinase domain is in an active-like conformation despite the lack of tyrosine phosphorylation in the activation loop. The unique features of the ATP-binding site, identified by structural and sequence comparison with other kinases, will be useful in the design of ZAP-70-selective inhibitors.The zeta-associated protein, 70 kDa (ZAP-70), 1 a Syk family tyrosine kinase associated with the subunit of the T cell receptor, is primarily expressed in T and NK cells and plays an essential role in signaling through the T cell receptor (TCR) (2, 3). TCR-mediated activation of T cells is crucial to the immune response. Transplant rejection and diseases, such as allergic responses and autoimmune disorders, stem from a failure to adequately modulate T cell activation. In humans, ZAP-70 gene mutations have been identified that confer lower ZAP-70 protein expression levels or catalytically inactive ZAP-70 proteins (4 -6). ZAP-70 deficiency results in the absence of mature CD8 ϩ T cells and the prevention of TCR-mediated activation of CD4 ϩ T cells, and it can lead to severe combined immunodeficiency. Peptides that block the association of ZAP-70 with the subunit (7,8) and peptides that antagonize ZAP-70 tyrosine kinase activity (9) block T cell activation in vitro. These studies indicate that ZAP-70 antagonists could be useful immunomodulatory therapeutic agents.ZAP-70 contains two N-terminal SH2 (Src homology domain 2) domains and a C-terminal kinase domain. During T cell activation, the binding of ZAP-70 SH2 domains to the phosphorylated subunit on the activated TCR complex causes a colocalization with the Lck tyrosine kinase that phosphorylates ZAP-70 on Tyr 493 in the activation loop (10, 11). Also, ZAP-70 autophosphorylates multiple tyrosines in the region between the SH2 domains and the kinase domain (10, 12), including the binding sites for additional SH2-containing signaling proteins such as SLP-76, Lat, Lck, PLC␥1, Vav, Shc, Ras-GAP, and Abl (reviewed in Refs. 8, 13, and 15). ZAP-70-mediated activation of these downstream effectors leads to the release of intracellular calcium stores, and the transcription of interleukin-2 and other ...